Meaningful Clinical Impact of ABvac40 in Early‐Stage Alzheimer’s Disease: Results from the AB1601 Phase 2 Study

ABvac40 treatment significantly reduced clinically meaningful cognitive decline, particularly in amyloid-PET positive patients, with the strongest effects in those with the highest antibody levels. These findings highlight ABvac40's potential to influence disease progression in early-stage AD and warrant further studies to explore its impact on brain vessels as potential driver of the observed cognitive benefits.